The mission of the Molecular Cytology Core is to deliver cutting-edge, specialized services in support of research projects at the Center. The methodologies employed by the Core allow for the detection in situ (in cells, tissue sections, organoids and whole mounts) of biomarkers (proteins, glycoproteins, lipids, nucleic acids) and molecular processess in normal and pathological conditions. The precise localization of the biomarkers is achieved by optical imaging of fixed and live samples. Several molecular markers (up to seven) can be vizualized simultanously or sequentially in the same sample by multiplex staining, using machine-based protocols. In collaboration with its users, the Core performs comprehensive antibody validations. The Core trains investigators in basic staining principles and assists them in performing manual experiments. The optical imaging modalities within the Core allow for wide field imaging and confocal imaging of tissue sections, thick and cleared tissue samples, cells, live embryos, tumors in live mice, etc. Super-resolution imaging is performed as well as confocal imaging in the IR range to visualize nanomaterials and drugs. With the newly acquired module for fluorescence correlation spectroscopy (FCS) imaging, researchers can study the dynamic behavior of biomolecules. The Core scans user slides with four digital slide scanners, one of which has confocal capabilities. The scanning generates large volumes of data and serves as a valuable resource for image analysis. Microscopy staff provides strong support for the users with 2D and 3D image analysis. The Core?s Atomic Force microscope is heavily used to study molecular interactions with nanometer resolution, to evaluate the effect of inhibitors on pathologic processes, and to assess stiffness of tissues from normal and cancer- bearing animals as well as tissues from cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-54
Application #
9858279
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
54
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Vickers, Andrew J; Steineck, Gunnar (2018) Prognosis, Effect Modification, and Mediation. Eur Urol 74:243-245
Jakub, James W; Peled, Anne Warren; Gray, Richard J et al. (2018) Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study. JAMA Surg 153:123-129
Ulaner, Gary A; Lyashchenko, Serge K; Riedl, Christopher et al. (2018) First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer. J Nucl Med 59:900-906
Brown, Fiona C; Still, Eric; Koche, Richard P et al. (2018) MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov 8:478-497
McFarland, Daniel C; Shaffer, Kelly M; Tiersten, Amy et al. (2018) Physical Symptom Burden and Its Association With Distress, Anxiety, and Depression in Breast Cancer. Psychosomatics 59:464-471
Aherne, Emily A; Plodkowski, Andrew J; Montecalvo, Joseph et al. (2018) What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology? Lung Cancer 118:83-89
Perrin, Thomas; Midya, Abhishek; Yamashita, Rikiya et al. (2018) Short-term reproducibility of radiomic features in liver parenchyma and liver malignancies on contrast-enhanced CT imaging. Abdom Radiol (NY) 43:3271-3278
Apte, Aditya P; Iyer, Aditi; Crispin-Ortuzar, Mireia et al. (2018) Technical Note: Extension of CERR for computational radiomics: A comprehensive MATLAB platform for reproducible radiomics research. Med Phys :
Santini, Fernando C; Rizvi, Hira; Plodkowski, Andrew J et al. (2018) Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer Immunol Res 6:1093-1099
Ma, Jennifer; Setton, Jeremy; Lee, Nancy Y et al. (2018) The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. Nat Commun 9:3292

Showing the most recent 10 out of 8799 publications